Tag:
Seattle Genetics
Latest Headlines
Latest Headlines
Ventana to work with Seattle Genetics, Millennium on companion Dx
The companion diagnostic trend continues--and Ventana Medical Systems is involved yet again. This morning, Seattle Genetics and Takeda's Millennium unit announced that they are working with the Roche company on a companion diagnostic test for use in a study involving Adcetris.
Seattle Genetics to test Adcetris in non-Hodgkin's patients
Fresh off an approval for Hodgkin's lymphoma and another rare lymphoma, Seattle Genetics ( $SGEN ) is launching a new trial of its Adcetris treatment in non-Hodgkin's lymphoma. The Phase II trial will
Seattle Genetics prices Adcetris above $100K
Yet another $100,000-plus cancer treatment will soon hit the market. Seattle Genetics, which won early FDA approval for its new lymphoma drug Adcetris, has tagged it with a $13,500-per-dose price,
UPDATED: FDA pins approval on Seattle Genetics' cancer drug Adcetris
Seattle Genetics ( $SGEN ) has crossed the finish line. The FDA has granted the biotech an accelerated approval for Adcetris to treat Hodgkin's lymphoma and anaplastic large cell lymphoma. While it's
Seattle Genetics' stock falls despite panel recommendation
Seattle Genetics' stock price fell to $19.17 in pre-market trading despite yesterday's expert panel recommendation accelerated approval of the company's drug, brentuximab vedotin (Adcetris).
UPDATED: Seattle Genetics lymphoma drug gets FDA panel nod
Seattle Genetics ( $SGEN ) can claim a victory today. An FDA panel of experts voted unanimously for accelerated approval of the developer's drug brentuximab vedotin (Adcetris) for patients with
Dendreon, cancer drug developers top slate of buyout candidates
This summer's been somewhat tame on the biotech mergers front. It's lacked a blockbuster deal on par with Sanofi's buyout of Genzyme, reports of which began last summer and kept biotech reporters
Seattle Genetics takes step closer with FDA review of lymphoma drug
The folks at Seattle Genetics ($SGEN) might rest a bit easier tonight heading into an advisory committee meeting that will consider its experimental lymphoma drug later this week. An FDA staff review
Seattle Genetics strikes again with $208M ADC deal with Abbott
Seattle Genetics ( $SGEN ) has racked up another collaboration pact involving its closely-watched antibody-drug conjugate technology. The red-hot ADC company is pocketing $8 million from Abbott
Millennium expands cancer pact with red-hot Seattle Genetics
Takeda's Millennium has opted to expand its antibody-drug conjugate deal with Seattle Genetics ( $SGEN ), paying an undisclosed fee to exercise an option to designate a second antigen target outlined
